Skip to main content Accessibility help
×
Hostname: page-component-77f85d65b8-8wtlm Total loading time: 0 Render date: 2026-04-16T12:41:57.186Z Has data issue: false hasContentIssue false

9a - Animal models of depressive illness and sickness behavior

from Section 2 - Cancer Symptom Mechanisms and Models: Clinical and Basic Science

Published online by Cambridge University Press:  05 August 2011

By
Adrian J. Dunn
Edited by
Charles S. Cleeland ,
Michael J. Fisch  and
Adrian J. Dunn
Adrian J. Dunn
Affiliation:
University of Hawaii at Manoa
Charles S. Cleeland
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Michael J. Fisch
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Adrian J. Dunn
Affiliation:
University of Hawaii, Manoa
Get access

Summary

For many patients with cancer, becoming depressed is frequently associated with both the cancer and its treatments. In a recent state-of-the-science conference, depression was highlighted as one of the most important symptoms facing patients with cancer, along with fatigue and pain. Only a small proportion of patients with cancer present with major depression as defined by the revised fourth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IVR), but depression-like symptoms, including reduced interest in previously pleasurable activities, lack of motivation, and sadness are frequently reported by patients with cancer in various stages of the disease.

It is easy to attribute these changes in affect to the patient learning that they have a potentially fatal disease. However, the degree of disturbance reported by patients is typically only modestly correlated with the severity of their disease or their prognosis. Only recently has there been interest in the association between the biological insults caused by cancer and its treatment, and the changes in affect and the other symptoms that patients report. Having a greater understanding of the biology contributing to cancer-related changes in affect should lead to better control or prevention of this source of distress.

Animal models of depressed affect related to disease burden or treatment toxicities may be important for developing a mechanistic understanding of why these changes occur. Currently, animal models of depressed affect related to cancer are relatively unexplored (but see below).

Information

Type
Chapter
Information
Cancer Symptom Science
Measurement, Mechanisms, and Management
 , pp. 82 - 94
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Patrick, DL, Ferketich, SL, Frame, PS, et al. National Institutes of Health State-of-the-Science Conference statement: symptom management in cancer: pain, depression, and fatigue, July 15–17, 2002. J Natl Cancer Inst 95(15):1110–1117, 2003.Google Scholar
,American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, revised 4th ed. Washington DC: American Psychiatric Association, 2000.Google Scholar
Granata, AR, Numao, Y, Kumada, M, Reis, DJ. A1 noradrenergic neurons tonically inhibit sympathoexcitatory neurons of C1 area in rat brainstem. Brain Res 377(1):127–146, 1986.CrossRefGoogle ScholarPubMed
McKinney, WT. Overview of the past contributions of animal models and their changing place in psychiatry. Semin Clin Neuropsychiatry 6(1):68–78, 2001.CrossRefGoogle Scholar
McKinney, WT. Animal models of depression: an overview. Psychiatr Dev 2(2):77–96, 1984.Google ScholarPubMed
Kalueff, AV, Tuohimaa, P. Experimental modeling of anxiety and depression. Acta Neurobiol Exp (Wars) 64(4):439–448, 2004.Google ScholarPubMed
McArthur, R, Borsini, F. Animal models of depression in drug discovery: a historical perspective. Pharmacol Biochem Behav 84(3):436–452, 2006.CrossRefGoogle ScholarPubMed
Anisman, H, Matheson, K. Stress, depression, and anhedonia: caveats concerning animal models. Neurosci Biobehav Rev 29(4–5):525–546, 2005.CrossRefGoogle ScholarPubMed
Maier, SF. Learned helplessness and animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 8(3):435–446, 1984.CrossRefGoogle ScholarPubMed
Seligman, ME, Maier, SF. Failure to escape traumatic shock. J Exp Psychol 74(1):1–9, 1967.CrossRefGoogle ScholarPubMed
Sherman, AD, Sacquitne, JL, Petty, F. Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 16(3):449–454, 1982.CrossRefGoogle Scholar
Henn, FA, Vollmayr, B. Stress models of depression: forming genetically vulnerable strains. Neurosci Biobehav Rev 29(4–5):799–804, 2005.CrossRefGoogle ScholarPubMed
Anisman, H, Zacharko, RM. Depression: the predisposing influence of stress. Behav Brain Sci 5(1):89–99, 1982.CrossRefGoogle Scholar
Praag, HM. Can stress cause depression?Prog Neuropsychopharmacol Biol Psychiatry 28(5):891–907, 2004.CrossRefGoogle ScholarPubMed
Willner, P. The validity of animal models of depression. Psychopharmacology (Berl) 83(1):1–16, 1984.CrossRefGoogle ScholarPubMed
Willner, P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 134(4):319–329, 1997.CrossRefGoogle ScholarPubMed
Ducottet, C, Griebel, G, Belzung, C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 27(4):625–631, 2003.CrossRefGoogle ScholarPubMed
Griebel, G, Simiand, J, Serradeil-Le Gal, C, et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A 99(9):6370–6375, 2002.CrossRefGoogle ScholarPubMed
Overstreet, DH, Pucilowski, O, Rezvani, AH, Janowsky, DS. Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Psychopharmacology (Berl) 121(1):27–37, 1995.CrossRefGoogle ScholarPubMed
Lachman, HM, Papolos, DF, Weiner, ED, et al. Hippocampal neuropeptide Y mRNA is reduced in a strain of learned helpless resistant rats. Brain Res Mol Brain Res 14(1–2):94–100, 1992.CrossRefGoogle Scholar
Weiss, JM, Kilts, CD. Animal models of depression and schizophrenia. In: Schatzberg, AF, Nemeroff, CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington DC: American Psychiatric Press, 1998:89–131.Google Scholar
Vaugeois, JM, Passera, G, Zuccaro, F, Costentin, J. Individual differences in response to imipramine in the mouse tail suspension test. Psychopharmacology (Berl) 134(4):387–391, 1997.CrossRefGoogle ScholarPubMed
Krömer, SA, Kessler, MS, Milfay, D, et al. Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci 25(17):4375–4384, 2005.CrossRefGoogle Scholar
El Yacoubi, M, Vaugeois, JM. Genetic rodent models of depression. Curr Opin Pharmacol 7(1):3–7, 2007.CrossRefGoogle ScholarPubMed
Porsolt, RD, Anton, G, Blavet, N, Jalfre, M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47(4):379–391, 1978.CrossRefGoogle ScholarPubMed
Porsolt, RD, Bertin, A, Jalfre, M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229(2):327–336, 1977.Google ScholarPubMed
Porsolt, RD, Pichon, M, Jalfre, M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266(5604):730–732, 1977.CrossRefGoogle ScholarPubMed
Steru, L, Chermat, R, Thierry, B, Simon, P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85(3):367–370, 1985.CrossRefGoogle ScholarPubMed
Porsolt, RD, Bertin, A, Jalfre, M. “Behavioural despair” in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 51(3):291–294, 1978.CrossRefGoogle ScholarPubMed
Cryan, JF, Markou, A, Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23(5):238–245, 2002.CrossRefGoogle ScholarPubMed
Lucki, I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8(6–7):523–532, 1997.CrossRefGoogle ScholarPubMed
Cryan, JF, Holmes, A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4(9):775–790, 2005.CrossRefGoogle ScholarPubMed
Cryan, JF, Valentino, RJ, Lucki, I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29(4–5):547–569, 2005.CrossRefGoogle ScholarPubMed
Chermat, R, Thierry, B, Mico, JA, Steru, L, Simon, P. Adaptation of the tail suspension test to the rat. J Pharmacol 17(3):348–350, 1986.Google ScholarPubMed
Harkin, A, Houlihan, DD, Kelly, JP. Reduction in preference for saccharin by repeated unpredictable stress in mice and its prevention by imipramine. J Psychopharmacol 16(2):115–123, 2002.CrossRefGoogle ScholarPubMed
Dunn, AJ, Swiergiel, AH. The reductions in sweetened milk intake induced by interleukin-1 and endotoxin are not prevented by chronic antidepressant treatment. Neuroimmunomodulation 9(3):163–169, 2001.CrossRefGoogle Scholar
Forbes, EE. Where's the fun in that? Broadening the focus on reward function in depression. Biol Psychiatry 66(3):199–200, 2009.CrossRefGoogle ScholarPubMed
Praag, HM. Serotonin precursors in the treatment of depression. Adv Biochem Psychopharmacol 34:259–286, 1982.Google ScholarPubMed
Schmitt, JA, Jorissen, BL, Sobczak, S, et al. Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. J Psychopharmacol 14(1):21–29, 2000.CrossRefGoogle ScholarPubMed
Bell, C, Abrams, J, Nutt, D. Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 178:399–405, 2001.CrossRefGoogle ScholarPubMed
Delgado, PL, Miller, HL, Salomon, RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46(2):212–220, 1999.CrossRefGoogle ScholarPubMed
Jacobs, BL. Adult brain neurogenesis and depression. Brain Behav Immun 16(5):602–609, 2002.CrossRefGoogle ScholarPubMed
Sahay, A, Hen, R. Adult hippocampal neurogenesis in depression. Nat Neurosci 10(9):1110–1115, 2007.CrossRefGoogle ScholarPubMed
Altman, J, Das, GD. Post-natal origin of microneurones in the rat brain. Nature 207(5000):953–956, 1965.CrossRefGoogle ScholarPubMed
Jacobs, BL, Praag, H, Gage, FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 5(3):262–269, 2000.CrossRefGoogle Scholar
Ming, GL, Song, H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci 28:223–250, 2005.CrossRefGoogle ScholarPubMed
Sapolsky, RM, Krey, LC, McEwen, BS. Glucocorticoid-sensitive hippocampal neurons are involved in terminating the adrenocortical stress response. Proc Natl Acad Sci U S A 81(19):6174–6177, 1984.CrossRefGoogle ScholarPubMed
Gould, E, Cameron, HA, Daniels, DC, Woolley, CS, McEwen, BS. Adrenal hormones suppress cell division in the adult rat dentate gyrus. J Neurosci 12(9):3642–3650, 1992.CrossRefGoogle ScholarPubMed
Gould, E, Tanapat, P, McEwen, BS, Flügge, G, Fuchs, E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci U S A 95(6):3168–3171, 1998.CrossRefGoogle ScholarPubMed
Martinowich, K, Lu, B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 33(1):73–83, 2008.CrossRefGoogle ScholarPubMed
Sargent, PA, Kjaer, KH, Bench, CJ, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57(2):174–180, 2000.CrossRefGoogle Scholar
Yoshimura, R, Mitoma, M, Sugita, A, et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31(5):1034–1037, 2007.CrossRefGoogle ScholarPubMed
Dunn, AJ, Swiergiel, AH, Cork, R, Newman, RA. Behavioral, neurochemical and neuroendocrine responses to leukemia in mice [abstract]. Society for Neuroscience 2004 Annual Meeting, San Diego CA, Oct 23–27, 2004. Abstract 462.13.Google Scholar
Lorenzetti, V, Allen, NB, Fornito, A, Yücel, M. Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord 117(1–2):1–17, 2009.CrossRefGoogle ScholarPubMed
Chuluyan, HE, Wolcott, RM, Chervenak, R, Dunn, AJ. Catecholamine, indoleamine and corticosteroid responses in mice bearing tumors. Neuroimmunomodulation 8(3):107–113, 2000.CrossRefGoogle ScholarPubMed
Pyter, LM, Pineros, V, Galang, JA, McClintock, MK, Prendergast, BJ. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc Natl Acad Sci U S A 106(22):9069–9074, 2009.CrossRefGoogle ScholarPubMed
Dantzer, R, O'Connor, JC, Freund, GG, Johnson, RW, Kelley, KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9(1):46–56, 2008.CrossRefGoogle Scholar
Miller, AH, Maletic, V, Raison, CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65(9):732–741, 2009.CrossRefGoogle ScholarPubMed
Miller, AH. Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface. Brain Behav Immun 23(2):149–158, 2009.CrossRefGoogle ScholarPubMed
Coussens, LM, Werb, Z. Inflammation and cancer. Nature 420(6917):860–867, 2002.CrossRefGoogle ScholarPubMed
Williams, J, Chen, Y, Rubin, P, Finkelstein, J, Okunieff, P. The biological basis of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):182–188, 2003.CrossRefGoogle ScholarPubMed
Hart, BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 12(2):123–137, 1988.CrossRefGoogle ScholarPubMed
Kent, S, Bluthé, RM, Kelley, KW, Dantzer, R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13(1):24–28, 1992.CrossRefGoogle ScholarPubMed
Dunn, AJ. Cytokine activation of the HPA axis. Ann N Y Acad Sci 917:608–617, 2000.CrossRefGoogle ScholarPubMed
Dunn, AJ, Wang, J, Ando, T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 461:117–127, 1999.CrossRefGoogle ScholarPubMed
Ando, T, Dunn, AJ. Mouse tumor necrosis factor-alpha increases brain tryptophan concentrations and norepinephrine metabolism while activating the HPA axis in mice. Neuroimmunomodulation 6(5):319–329, 1999.CrossRefGoogle ScholarPubMed
Larson, SJ, Dunn, AJ. Behavioral effects of cytokines. Brain Behav Immun 15(4):371–387, 2001.CrossRefGoogle ScholarPubMed
Dantzer, R, Bluthé, RM, Castanon, N, et al. Cytokine effects on behavior. In: Ader, R, Felten, DL, Cohen, N, eds. Psychoneuroimmunology. San Diego, CA: Academic Press, 2001:703–727.Google Scholar
Swiergiel, AH, Dunn, AJ. Feeding, exploratory, anxiety- and depression-related behaviors are not altered in interleukin-6-deficient male mice. Behav Brain Res 171(1):94–108, 2006.CrossRefGoogle Scholar
Wang, J, Dunn, AJ. Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem Int 33(2):143–154, 1998.CrossRefGoogle ScholarPubMed
Bluthé, RM, Michaud, B, Poli, V, Dantzer, R. Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice. Physiol Behav 70(3–4):367–373, 2000.CrossRefGoogle ScholarPubMed
Bluthé, RM, Layé, S, Michaud, B, Combe, C, Dantzer, R, Parnet, P. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur J Neurosci 12(12):4447–4456, 2000.Google ScholarPubMed
Yirmiya, R, Pollak, Y, Barak, O, et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 24(5):531–544, 2001.CrossRefGoogle Scholar
Castanon, N, Bluthé, RM, Dantzer, R. Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl) 154(1):50–60, 2001.CrossRefGoogle Scholar
Castanon, N, Konsman, JP, Médina, C, Chauvet, N, Dantzer, R. Chronic treatment with the antidepressant tianeptine attenuates lipopolysaccharide-induced Fos expression in the rat paraventricular nucleus and HPA axis activation. Psychoneuroendocrinology 28(1):19–34, 2003.CrossRefGoogle ScholarPubMed
Maes, M. A review on the acute phase response in major depression. Rev Neurosci 4(4):407–416, 1993.CrossRefGoogle ScholarPubMed
Maes, M, Bosmans, E, Suy, E, Vandervorst, C, DeJonckheere, C, Raus, J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 84(4):379–386, 1991.CrossRefGoogle ScholarPubMed
Schlatter, J, Ortuño, F, Cervera-Enguix, S. Lymphocyte subsets and lymphokine production in patients with melancholic versus nonmelancholic depression. Psychiatry Res 128(3):259–265, 2004.CrossRefGoogle ScholarPubMed
Weizman, R, Laor, N, Podliszewski, E, Notti, I, Djaldetti, M, Bessler, H. Cytokine production in major depressed patients before and after clomipramine treatment. Biol Psychiatry 35(1):42–47, 1994.CrossRefGoogle ScholarPubMed
Anisman, H, Ravindran, AV, Griffiths, J, Merali, Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 4(2):182–188, 1999.CrossRefGoogle ScholarPubMed
Thomas, AJ, Davis, S, Morris, C, Jackson, E, Harrison, R, O'Brien, JT. Increase in interleukin-1beta in late-life depression. Am J Psychiatry 162(1):175–177, 2005.CrossRefGoogle ScholarPubMed
Owen, BM, Eccleston, D, Ferrier, IN, Young, AH. Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr Scand 103(3):226–228, 2001.CrossRefGoogle ScholarPubMed
Yang, K, Xie, G, Zhang, Z, et al. Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression. Aust N Z J Psychiatry 41(3):266–273, 2007.CrossRefGoogle ScholarPubMed
Brambilla, F, Maggioni, M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand 97(4):309–313, 1998.CrossRefGoogle ScholarPubMed
Brambilla, F, Monteleone, P, Maj, M. Interleukin-1beta and tumor necrosis factor-alpha in children with major depressive disorder or dysthymia. J Affect Disord 78(3):273–277, 2004.CrossRefGoogle ScholarPubMed
Kagaya, A, Kugaya, A, Takebayashi, M, et al. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 43(2):59–62, 2001.CrossRefGoogle ScholarPubMed
Huang, TL, Lee, CT. T-helper 1/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression. Psychiatry Clin Neurosci 61(4):415–420, 2007.CrossRefGoogle ScholarPubMed
Rothermundt, M, Arolt, V, Fenker, J, Gutbrodt, H, Peters, M, Kirchner, H. Different immune patterns in melancholic and non-melancholic major depression. Eur Arch Psychiatry Clin Neurosci 251(2):90–97, 2001.CrossRefGoogle ScholarPubMed
Rothermundt, M, Arolt, V, Peters, M, et al. Inflammatory markers in major depression and melancholia. J Affect Disord 63(1–3):93–102, 2001.CrossRefGoogle ScholarPubMed
Milaneschi, Y, Corsi, AM, Penninx, BW, Bandinelli, S, Guralnik, JM, Ferrucci, L. Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study. Biol Psychiatry 65(11):973–978, 2009.CrossRefGoogle ScholarPubMed
Ovaskainen, Y, Koponen, H, Jokelainen, J, Keinänen-Kiukaanniemi, S, Kumpusalo, E, Vanhala, M. Depressive symptomatology is associated with decreased interleukin-1 beta and increased interleukin-1 receptor antagonist levels in males. Psychiatry Res 167(1–2):73–79, 2009.CrossRefGoogle ScholarPubMed
Rothermundt, M, Arolt, V, Bayer, TA. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 15(4):319–339, 2001.CrossRefGoogle Scholar
Zorrilla, EP, Luborsky, L, McKay, JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 15(3):199–226, 2001.CrossRefGoogle ScholarPubMed
Howren, MB, Lamkin, DM, Suls, J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71(2):171–186, 2009.CrossRefGoogle ScholarPubMed
Dowlati, Y, Herrmann, N, Swardfager, W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry:e-pub ahead of print, 2009.Google ScholarPubMed
Dunn, AJ, Swiergiel, AH. Cytokines and stress: neurochemistry, endocrinology and behavior. In: McCarty, R, Aguilera, G, Sabban, E, Kvetnanský, R, eds. Stress: Neural, Endocrine, and Molecular Studies. London: Taylor & Francis, 2002:163–166.Google Scholar
Quan, N, Banks, WA. Brain-immune communication pathways. Brain Behav Immun 21(6):727–735, 2007.CrossRefGoogle ScholarPubMed
Levine, J, Barak, Y, Chengappa, KN, Rapoport, A, Rebey, M, Barak, V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40(4):171–176, 1999.CrossRefGoogle ScholarPubMed
Dunn, AJ, Swiergiel, AH. Effects of acute and chronic stressors and CRF in rat and mouse tests for depression. Ann N Y Acad Sci 1148:118–126, 2008.CrossRefGoogle Scholar
Maier, SF, Seligman, MEP. Learned helplessness: theory and evidence. J Exp Psychol Gen 105(1):3–46, 1976.CrossRefGoogle Scholar
Yirmiya, R, Pollak, Y, Morag, M, et al. Illness, cytokines, and depression. Ann N Y Acad Sci 917:478–487, 2000.CrossRefGoogle ScholarPubMed
Swiergiel, AH, Dunn, AJ. The roles of IL-1, IL-6, and TNFalpha in the feeding responses to endotoxin and influenza virus infection in mice. Brain Behav Immun 13(3):252–265, 1999.CrossRefGoogle ScholarPubMed

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the PDF of this chapter is currently unknown and may be updated in the future.

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×